Interferon‐free regimens are associated with high sustained virological response.
However, associated adverse effects have yet to be fully reported.
Dr Esmat and colleagues evaluated the adverse effects associated with the different direct‐acting antiviral drug (DAA) regimens in Egyptian patients.
The researchers performed a multicenter retrospective study including all adverse effects during and after treatment with DAA regimens of 149,816 chronic hepatitis C treated Egyptian patients.
Patients received sofosbuvir (SOF)/ribavirin (RBV), SOF/simeprevir, SOF/daclatasvir (DCV), SOF/DCV/RBV, and paritaprevir/ombitasvir/ritonavir/RBV.
|Adverse effects developed in 2% of patients|
|Alimentary Pharmacology & Therapeutics|
The research team found that the duration of treatment varied between 12 and 24 weeks.
All changes in the treatment regimens, discontinuation, mortality, and serious side effects were reported.
The researchers noted that adverse effects developed in 2% of patients.
Serious side effects developed in 68% of these patients, and SOF/RBV was the most common causing regimen.
The team noted that anemia and hyperbilirubinemia were the most common side effects, and SOF/RBV showed the highest incidence in the treated patients.
Hepatocellular carcinoma and mortality were reported in less than 1% of all treated patients, respectively.
Patients with liver cirrhosis showed higher incidence of serious side effects and mortality than patients without liver cirrhosis.
Male gender, lower hemoglobin, platelets and albumin, higher bilirubin and cirrhosis were factors associated with serious side effects development.
Dr Esmat's team comments, "Adverse effects associated with DAAs are few, anaemia being the most common."
"SOF/RBV regimen showed the highest rate of side effects while SOF/DCV showed the least."